ReviewFrontiers in medicine2025

Dual SGLT1/2 inhibition with sotagliflozin: a pharmaceutical breakthrough in heart failure management and cardiometabolic risk reduction.

Ghaith K Mansour et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.